|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **TABLE S2. Mortality rate ratios for log2-transformed suPAR within NEWS groups for patients with cardiovascular disease, cancer, or renal disease** | | | | | | | | | | | | | |
|  |  |  | **In-hospital mortality** | | |  | **30-day mortality** | | |  | **90-day mortality** | | |
| **Subgroup** | **n** |  | **Died,**  **n (%)** | **MRR (95% CI)** | **P** |  | **Died,**  **n (%)** | **MRR (95% CI)** | **P** |  | **Died,**  **n (%)** | **MRR (95% CI)** | **P** |
| **CVD** | 2,989 |  | 204 (6.8) |  |  |  | 291 (9.7) |  |  |  | 462 (15.5) |  |  |
| NEWS 0–1 | 1,416 |  | 24 (1.7) | 2.96 (1.86–4.72) | <0.0001 |  | 46 (3.3) | 3.32 (2.39–4.62) | <0.0001 |  | 100 (7.1) | 3.08 (2.46–3.86) | <0.0001 |
| NEWS 2 | 397 |  | 16 (4.0) | 2.44 (1.34–4.44) | 0.0035 |  | 36 (9.1) | 2.02 (1.35–3.04) | 0.0007 |  | 69 (17.4) | 2.18 (1.63–2.90) | <0.0001 |
| NEWS 3–5 | 646 |  | 65 (10.1) | 1.63 (1.19–2.22) | 0.0024 |  | 84 (13.0) | 2.08 (1.58–2.73) | <0.0001 |  | 125 (19.4) | 2.06 (1.65–2.58) | <0.0001 |
| NEWS 6 | 146 |  | 21 (14.4) | 1.39 (0.76–2.54) | 0.28 |  | 29 (19.9) | 1.56 (0.94–2.57) | 0.083 |  | 44 (30.1) | 2.12 (1.40–3.23) | 0.0004 |
| NEWS 7–8 | 151 |  | 27 (17.9) | 1.16 (0.67–2.02) | 0.60 |  | 35 (23.2) | 1.57 (0.94–2.62) | 0.085 |  | 48 (31.8) | 2.00 (1.30–3.09) | 0.0017 |
| NEWS ≥9 | 114 |  | 38 (33.3) | 2.11 (1.38–3.24) | 0.0006 |  | 46 (40.4) | 2.10 (1.38–3.19) | 0.0005 |  | 56 (49.1) | 1.84 (1.22–2.77) | 0.0036 |
| **Cancer** | 1,314 |  | 169 (12.9) |  |  |  | 250 (19.0) |  |  |  | 420 (32.0) |  |  |
| NEWS 0–1 | 564 |  | 28 (5.0) | 1.99 (1.30–3.04) | 0.0015 |  | 58 (10.3) | 3.16 (2.39–4.19) | <0.0001 |  | 107 (19.0) | 3.13 (2.52–3.88) | <0.0001 |
| NEWS 2 | 177 |  | 18 (10.2) | 2.13 (1.32–3.44) | 0.0020 |  | 34 (19.2) | 2.34 (1.59–3.45) | <0.0001 |  | 68 (38.4) | 2.21 (1.64–2.97) | <0.0001 |
| NEWS 3–5 | 307 |  | 55 (17.9) | 1.90 (1.38–2.62) | <0.0001 |  | 78 (25.4) | 2.23 (1.71–2.92) | <0.0001 |  | 120 (39.1) | 2.19 (1.76–2.72) | <0.0001 |
| NEWS 6 | 67 |  | 5 (7.5) | 0.67 (0.23–1.95) | 0.46 |  | 11 (16.4) | 1.84 (0.85–3.99) | 0.12 |  | 25 (37.3) | 1.85 (1.13–3.05) | 0.015 |
| NEWS 7–8 | 84 |  | 22 (26.2) | 2.40 (1.47–3.91) | 0.0005 |  | 24 (28.6) | 2.58 (1.49–4.46) | 0.0007 |  | 42 (50.0) | 2.14 (1.44–3.19) | 0.0002 |
| NEWS ≥9 | 59 |  | 31 (52.5) | 1.90 (1.21–2.98) | 0.0056 |  | 33 (55.9) | 2.00 (1.17–3.42) | 0.011 |  | 40 (67.8) | 1.81 (1.11–2.95 | 0.017 |
| **Renal disease** | 368 |  | 44 (12.0) |  |  |  | 52 (14.1) |  |  |  | 86 (23.4) |  |  |
| NEWS 0–1 | 154 |  | 6 (3.9) | 4.38 (0.87–22.1) | 0.074 |  | 7 (4.6) | 4.16 (1.20–14.4) | 0.025 |  | 20 (13.0) | 4.44 (2.12–9.30) | <0.0001 |
| NEWS 2 | 45 |  | 3 (6.7) | 0.33 (0.04–2.89) | 0.32 |  | 4 (8.9) | 0.59 (0.13–2.76) | 0.50 |  | 8 (17.8) | 1.45 (0.42–5.00) | 0.56 |
| NEWS 3–5 | 91 |  | 20 (22.0) | 1.67 (0.93–2.98) | 0.086 |  | 21 (23.1) | 1.82 (1.03–3.22) | 0.040 |  | 28 (30.8) | 1.53 (0.94–2.50) | 0.090 |
| NEWS 6 | 28 |  | 4 (14.3) | 2.51 (0.30–21.0) | 0.40 |  | 6 (21.4) | 3.73 (0.60–23.2) | 0.16 |  | 9 (32.1) | 5.69 (1.19–27.1) | 0.029 |
| NEWS 7–8 | 26 |  | 6 (23.1) | 11.42 (0.83–156. 7) | 0.068 |  | 7 (26.9) | 2.53 (0.49–13.0) | 0.27 |  | 11 (42.3) | 3.75 (1.09–12.9) | 0.036 |
| NEWS ≥9 | 13 |  | 3 (23.1) | 0.85 (0.09–8.05) | 0.89 |  | 5 (38.5) | 3.00 (0.73–12.2) | 0.13 |  | 7 (53.9) | 2.62 (0.75–9.12) | 0.13 |
| CI, confidence interval; CVD, cardiovascular disease; MRR, mortality rate ratio; NEWS, national early warning score; suPAR, soluble urokinase plasminogen activator receptor.  Patients with missing NEWS omitted from Poisson regression analysis: CVD n=119, cancer n=56, renal disease n=11 | | | | | | | | | | | | | |